Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
Lumos Pharma(US:LUMO) Newsfilter·2024-05-20 20:05AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1- 4, 2024. Investor & Media Contact: Poster Session P069 – Monday June 3, 12:00-1:30 PM ET Lisa M ...